Dovato
Tablet, film coated · Oral · Prescription
Boxed warning
All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.
Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment [see Warnings and Precautions (5.1)].
Uses
DOVATO is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO.
From the FDA label of Viiv Healthcare Company, version of Oct 29, 2025. Not medical advice: ask your doctor or pharmacist.
Active ingredients
- Dolutegravir sodium
- Lamivudine
Generic name
- dolutegravir sodium and lamivudine
Drug class
- HIV Integrase Inhibitors
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
- Nucleoside Reverse Transcriptase Inhibitors
- Organic Cation Transporter 2 Inhibitors
What it looks like
| Imprint | Look | Manufacturer |
|---|---|---|
| SV 137 | White, Oval, 19 mm | Viiv Healthcare Company |
Inactive ingredients and allergens
The labels list none of the common allergens and intolerances (lactose, gluten, gelatin, tartrazine, peanut, soy and others).
- Viiv Healthcare Company, 50 mg/1, 300 mg/1: magnesium stearate, mannitol, microcrystalline cellulose, povidone k30, sodium starch glycolate type a corn, sodium stearyl fumarate, hypromellose, unspecified, polyethylene glycol, unspecified, titanium dioxide
From each product's FDA label; they differ between manufacturers and strengths. The app shows every product and finds those without an allergen.
Official FDA label
- Viiv Healthcare Company on DailyMed, version of Oct 29, 2025
Read the full label as text, with its contents and search, in the app.
Data: FDA NDC Directory, DailyMed labels, Orange Book, Purple Book and Enforcement Reports, updated Nov 17, 2026.